HT
NKTR icon

Headlands Technologies’s Nektar Therapeutics NKTR Stock Holding History

Headlands Technologies’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-28,244
Closed -$2.03M – 906
2026
Q1 		$2.03M Sell
28,244
-12,957
-31% -$738K 0.23% 86
2025
Q4 		$1.74M Buy
41,201
+11,371
+38% +$636K 0.15% 164
2025
Q3 		$1.7M Buy
29,830
+27,308
+1,083% +$904K 0.14% 167
2025
Q2 		$65.2K Buy
+2,522
New +$28.3K 0.01% 721

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Headlands Technologies's NKTR Position: Q2 2026 in Review

Headlands Technologies sold out of Nektar Therapeutics (NKTR) in Q2 2026, closing a stake of 28,244 shares — an estimated $2.03M sold.

Headlands Technologies first reported a position in NKTR in Q2 2025 and held it in 4 quarters. The position peaked at $2.03M in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Headlands Technologies reported no remaining Nektar Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Headlands Technologies sold 28,244 Nektar Therapeutics shares in Q2 2026, an estimated $2.03M.
  • Headlands Technologies first reported a position in Nektar Therapeutics in Q2 2025 and held it in 4 quarters.
  • Headlands Technologies's Nektar Therapeutics position peaked at $2.03M in Q1 2026.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.